Unique ID issued by UMIN | UMIN000029465 |
---|---|
Receipt number | R000033668 |
Scientific Title | Subtype Classification Consortium for Esophageal Squamous cell carcinoma Sensitivity of CROC study (UMIN000008086) |
Date of disclosure of the study information | 2017/10/11 |
Last modified on | 2021/10/13 21:44:28 |
Subtype Classification Consortium for Esophageal Squamous cell carcinoma Sensitivity of CROC study (UMIN000008086)
CROC-G study
Subtype Classification Consortium for Esophageal Squamous cell carcinoma Sensitivity of CROC study (UMIN000008086)
CROC-G study
Japan |
Esophageal cancer
Gastroenterology | Hematology and clinical oncology | Gastrointestinal surgery |
Malignancy
YES
To do subtype classification of esophageal cancer by profiling the gene expression of pretreatment biopsy sample
Others
Prospective cohort study
Subtype classification of esophageal cancer
Correlation between subtype classification and curative effects
Observational
20 | years-old | <= |
75 | years-old | >= |
Male and Female
1) Diagnosed squamous cell carcinoma by endoscopic biopsy.
2) Confirmed the lesion of thoracic esophagus (An accessory lesion of EMR absolute criteria may not be localized thoracic esophagus).
3) Clinical stage II/III without T4 in TNM classification (UICC6th).
4) Age more than 20years and less than 75 years.
5) PS(ECOG) of 0 or 1.
6) No previous treatment expect endoscopic resection of esophageal cancer.
7) No previous chemotherapy or radiation therapy for other malignancy.
8) No severe organ failure.
9) Possibility of transthoracic and/or transabdominal curative resection of esophageal cancer.
10) Signed informed consent of the patient for the registration.
1) An active malignancy other than carcinoma in situ or mucosal carcinoma or a history of other malignancy within the past 5 years.
2) Women who are pregnant, lactating, or wish to become pregnant.
3) Unsuitable mental status and condition for clinical trials.
4) Received continuous steroids (orally or intravenous) administration.
5) Positive HBs antigen.
6) Unstable diabetes mellitus with oral hypoglycemic agent or insulin.
7) Acute myocardial infarction within the past 3 months.
8) Severe complications (COPD, interstitial lung disease, pulmonary fibrosis, heart failure and so on) .
9) Active bacterial or fungous infection(body temperature more than 38.5 degrees and proved bacterial infection by diagnostic imaging or bacteriological examination ) .
10) Any other cases who are regarded as inadequate for study enrollment by the investigator.
100
1st name | Chikatoshi |
Middle name | |
Last name | Katada |
Kitasato University School of Medicine
Department of Gastroenterology
252-0374
1-15-1 Kitasato, Sagamihara, Kanagawa, 252-0374, Japan
042-778-8111
ckatada@med.kitasato-u.ac.jp
1st name | Chikatoshi |
Middle name | |
Last name | Katada |
Kitasato University School of Medicine
Department of Gastroenterology
252-0374
1-15-1 Kitasato, Sagamihara, Kanagawa, 252-0374, Japan
042-778-8111
ckatada@med.kitasato-u.ac.jp
Department of Gastroenterology, Kitasato University School of Medicine
Yakult Honsha Co., Ltd.
Profit organization
Clinical research review board of the Kitasato Institute
1-15-1 Kitasato, Minami, Sagamihara, Japan.
042-778-8111
rinrib@med.kitasato-u.ac.jp
NO
2017 | Year | 10 | Month | 11 | Day |
None
Unpublished
None
71
No longer recruiting
2017 | Year | 09 | Month | 20 | Day |
2012 | Year | 04 | Month | 18 | Day |
2017 | Year | 12 | Month | 01 | Day |
2022 | Year | 12 | Month | 03 | Day |
For CROC trial (UMIN000008086) patients
2017 | Year | 10 | Month | 07 | Day |
2021 | Year | 10 | Month | 13 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033668